[go: up one dir, main page]

PL3365438T3 - Zoptymalizowane względem kodonów cdna atp7a o zmniejszonej wielkości i zastosowania w leczeniu zaburzeń transportu miedzi - Google Patents

Zoptymalizowane względem kodonów cdna atp7a o zmniejszonej wielkości i zastosowania w leczeniu zaburzeń transportu miedzi

Info

Publication number
PL3365438T3
PL3365438T3 PL16794111T PL16794111T PL3365438T3 PL 3365438 T3 PL3365438 T3 PL 3365438T3 PL 16794111 T PL16794111 T PL 16794111T PL 16794111 T PL16794111 T PL 16794111T PL 3365438 T3 PL3365438 T3 PL 3365438T3
Authority
PL
Poland
Prior art keywords
codon
treatment
copper transport
transport disorders
optimized reduced
Prior art date
Application number
PL16794111T
Other languages
English (en)
Inventor
Stephen G. Kaler
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of PL3365438T3 publication Critical patent/PL3365438T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03004Cu2+-exporting ATPase (3.6.3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16794111T 2015-10-21 2016-10-21 Zoptymalizowane względem kodonów cdna atp7a o zmniejszonej wielkości i zastosowania w leczeniu zaburzeń transportu miedzi PL3365438T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562244594P 2015-10-21 2015-10-21
PCT/US2016/058124 WO2017070472A1 (en) 2015-10-21 2016-10-21 Codon-optimized reduced-size atp7a cdna and uses for treatment of copper transport disorders
EP16794111.1A EP3365438B1 (en) 2015-10-21 2016-10-21 Codon-optimized reduced-size atp7a cdna and uses for treatment of copper transport disorders

Publications (1)

Publication Number Publication Date
PL3365438T3 true PL3365438T3 (pl) 2021-10-18

Family

ID=57256420

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16794111T PL3365438T3 (pl) 2015-10-21 2016-10-21 Zoptymalizowane względem kodonów cdna atp7a o zmniejszonej wielkości i zastosowania w leczeniu zaburzeń transportu miedzi

Country Status (12)

Country Link
US (3) US10988778B2 (pl)
EP (1) EP3365438B1 (pl)
JP (2) JP6854286B2 (pl)
CN (1) CN108431216B (pl)
AU (1) AU2016341983B8 (pl)
CA (1) CA3001574A1 (pl)
DK (1) DK3365438T3 (pl)
ES (1) ES2879400T3 (pl)
HU (1) HUE054802T2 (pl)
PL (1) PL3365438T3 (pl)
PT (1) PT3365438T (pl)
WO (1) WO2017070472A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014594A1 (en) * 2018-07-12 2020-01-16 The Taxas A&M University System Compositions for the treatment of copper deficiency and methods of use
EP4308104A4 (en) * 2021-03-18 2025-03-12 Cyprium Therapeutics, Inc. Copper histidine compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017321A1 (en) 1992-02-25 1993-09-02 Unisearch Limited Electrothermal atomic absorption and preconcentration device
DE606516T1 (de) 1993-01-13 1995-03-16 Idemitsu Kosan Co Gegen menschlichen Ceruloplasmin monoklonaler Antikörper.
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
KR100459644B1 (ko) 2001-03-31 2004-12-03 제노백(주) 혈액 여과지에서의 효소면역측정법을 이용한셀룰로플라스민 농도 측정 방법 및 이 방법을 이용한윌슨병 스크리닝 검사용 키트와 진단 시약
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20070161120A1 (en) 2006-01-10 2007-07-12 Viorica Lopez-Avila Ceruloplasmin Assay
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
AU2009209408B2 (en) 2008-01-29 2015-06-11 Beacon Therapeutics Limited Recombinant virus production using mammalian cells in suspension
WO2010042102A1 (en) * 2008-10-06 2010-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of subjects likely to benefit from copper treatment
WO2010071832A1 (en) * 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
EP2814958B1 (en) * 2012-02-17 2019-08-07 The Children's Hospital of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
CN108949772A (zh) * 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
JP2015518704A (ja) * 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 膜タンパク質の産生のための修飾ポリヌクレオチド

Also Published As

Publication number Publication date
JP2018533941A (ja) 2018-11-22
US10988778B2 (en) 2021-04-27
DK3365438T3 (da) 2021-07-12
EP3365438A1 (en) 2018-08-29
AU2016341983B8 (en) 2022-10-06
HUE054802T2 (hu) 2021-09-28
AU2016341983B2 (en) 2022-05-26
JP2021052796A (ja) 2021-04-08
AU2016341983A1 (en) 2018-04-26
US20250129382A1 (en) 2025-04-24
CN108431216B (zh) 2022-08-05
US12173306B2 (en) 2024-12-24
WO2017070472A1 (en) 2017-04-27
CA3001574A1 (en) 2017-04-27
CN108431216A (zh) 2018-08-21
US20210214751A1 (en) 2021-07-15
JP6854286B2 (ja) 2021-04-07
AU2016341983A8 (en) 2022-10-06
PT3365438T (pt) 2021-07-12
ES2879400T3 (es) 2021-11-22
US20180312871A1 (en) 2018-11-01
EP3365438B1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL254116A0 (en) Treatment of pancreatitis
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
IL256186A (en) Treatment of nut midline carcinoma
IL254155A0 (en) pain treatment
GB201408387D0 (en) Treatment of respiratory disorders
ZA201802376B (en) Compositions and methods for treatment of homocystinuria
IL253026A0 (en) Calcitonin analogs for the treatment of diseases and disorders
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL256413B (en) IL-8 inhibitors for use in the treatment of certain urological disorders
PT3365438T (pt) Adnc com codão otimizado para atp7a de tamanho reduzido e utilização para o tratamento de distúrbios de transporte de cobre
PL3182980T3 (pl) Leczenie chorób niedoboru glikozylacji
PT3212586T (pt) Utilização de uma liga de crómio-alumina em tratamento térmico
GB201521442D0 (en) Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders
GB201516230D0 (en) Complexes of copper and silver
GB201613350D0 (en) Treatment of hyperpigmentation
GB201513922D0 (en) Treatment of hyperpigmentation